MISSION STATEMENT: Gentris Corporation will lead the new paradigm in healthcare by enabling the administration of medication based on individual genetic variation by offering high quality pharmacogenomic laboratory testing services and diagnostic products.

TYPE OF COMPANY: Pharmacogenomic services and diagnostic product solutions

ADDRESS: 133 Southcenter Court, Suite 400, Morrisville, NC 27560

PHONE NUMBER: 919.465.0100

WEB SITE: www.gentris.com


Michael Murphy, Chief Executive officer, is recognized as one of the pioneers of the pharmacogenomics industry and was the founder of Intek Labs (now Genaissance Laboratories), the first international pharmacogenomics company. Michael brings more than 22 years of scientific and business experience in the field of pharmacogenomics. He has also held senior management positions with PPGx and Clingenix, Inc. Michael is a frequent lecturer and author on pharmacogenomic topics. He serves on several committees that provide recommendations and industry insight on regulatory and reimbursement issues. Michael received his B.S. and M.S. degrees from San Diego State University and was trained in molecular biology at the Salk Institute

Deborah Oronzio, Vice President, Business Development and Marketing, has extensive clinical diagnostics industry experience having served in increasingly responsible management positions with Becton Dickinson, Pharmacia Diagnostics, Digene Corporation and Organon Teknika. She was instrumental in building a team of business development and marketing professionals when she served as VP Business Development and Marketing for PPD/PPGx.

Sandra Sonnessa, Vice President, Corporate Development has 25 years experience in the healthcare industry in positions with increasing responsibility in pharmaceutical and contract research organizations. In addition to marketing, sales, and business development positions at Bristol-Myers Squibb, Wyeth, and Medco, Ms. Sonnessa held senior management positions at Quintiles Transnational leading global business development and marketing for early clinical development, laboratory management, clinical supplies packaging, and Phase IIIB/IV drug development.

Dr. L. Scott Clark, Ph.D., Executive Director, Clinical Genetics, is a pioneer and industry leader in the application of pharmacogenomics in drug development with over 15 years of experience at pharmaceutical and clinical research companies in technology assessment and applications, assay development, laboratory management and project management. Dr. Clark worked at Intek Labs as Clinical Study Director following the successful completion of his post-doctoral training at the Environmental Protection Agency.

Dr. Pamela Nakhle, Ph.D., Executive Director, Product Development, has over 13 years experience conducting biological research, including 3 years experience developing products for nucleic acid detection. She has been involved in the development of novel electrochemical sensors for the detection of DNA and RNA.

Dawn L. Bordeaux, Vice President, Quality Assurance and Regulatory Affairs has 13 years of experience in operations, specializing in start-up companies and emerging pharmacogenomics companies. Ms. Bordeaux has been instrumental in the development and implementation of Good Laboratory Practice (21CFR58), study and process guidelines, performance metrics as well as laboratory Standard Operating Procedures and Quality Assurance.

Karen Nield, CPA, Executive Director, Finance, has over 13 years of broad range Public and Private Industry accounting experience. She has worked internationally in the Transaction Services Mergers and Acquisitions division of PriceWaterhouseCoopers based in Washington, DC.

BOARD MEMBERS: Margaret A. Humphrey, M.D., Bud Whitmeyer, Michael, Murphy

INVESTORS (and amounts raised, if possible):
Series A. funding: $1.46 Angel and Venture Capital
Series B. funding: $1. 62 Angel and Venture Capital

REVENUES: 2004, $2.3m